Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Generic Pharmaceuticals Contract Manufacturing Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The market size for generic pharmaceuticals contract manufacturing has shown substantial growth in recent years. It is anticipated to expand from $66.82 billion in 2025 to $71.65 billion in 2026, at a compound annual growth rate (CAGR) of 7.2%. The growth observed during the past period stemmed from factors such as limited contract manufacturing alternatives, a reliance on in-house generic drug manufacturing, an increasing demand for off-patent APIs, a rise in generic drug approvals, and cost containment pressures affecting pharmaceutical companies.
The generic pharmaceuticals contract manufacturing market is projected to experience substantial expansion in the coming years. Its value is forecast to reach $93.56 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.9%. This anticipated growth is due to several factors, including an increase in worldwide generic drug demand, the enlargement of contract manufacturing organizations (CMOs), the integration of sophisticated formulation technologies, a heightened emphasis on biologics and intricate generics, and stronger international regulatory partnerships. Key trends during this period are expected to encompass a surge in the outsourcing of generic drug production, an emphasis on economical production and packaging methods, the broadening of services for manufacturing injectables and tablets, enhanced regulatory assistance and compliance provisions, and an increase in licensing and technology transfer for generic items.
Get A Free Sample Report With In-Depth Market Insights:
Generic Pharmaceuticals Contract Manufacturing Market Growth Drivers: What’s Behind The Acceleration?
The increasing demand for biosimilars is anticipated to drive the expansion of the generic pharmaceuticals contract manufacturing market moving forward. Biosimilars are biological medical products that are very similar to already approved reference biologics, showing no clinically meaningful differences in their safety, purity, or potency. This growing demand for biosimilars primarily stems from their capacity to offer cost-effective alternatives to expensive biologic drugs, thereby enhancing the accessibility of advanced treatments for patients and healthcare systems. Generic pharmaceuticals contract manufacturing supports biosimilars by providing economical, large-scale production capabilities and the necessary regulatory expertise to accelerate their market entry and ensure consistent quality. For instance, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, as of January 2022, the U.S. had 33 biosimilar products approved by the FDA, with 21 of them available on the market and by 2023, the number of FDA-approved biosimilars had risen to 40, with 25 commercially available. Thus, the escalating demand for biosimilars is propelling the growth of the generic pharmaceuticals contract manufacturing market.
Generic Pharmaceuticals Contract Manufacturing Market Segmentation: How Does The Market Break Down By Category?
The generic pharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Drug Type: Branded Generics, Unbranded Generics
2) By Product Type: Pharmaceutical Active Pharmaceutical Ingredients, Formulations, Capsules, Tablets, Injectables
3) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
4) By Application: Oncology, Immunology, Antidiabetic, Neurology, Anticoagulants, Cardiovascular, Respiratory, Pain, Human Immunodeficiency Virus Antivirals
5) By End-User Industry: Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Generic Drug Manufacturers
Subsegments:
1) By Branded Generics: Contract Development of Branded Formulations, Branded Generic Tablet Manufacturing, Branded Injectable Manufacturing, Packaging and Labeling for Branded Generics, Regulatory Support For Branded Generics
2) By Unbranded Generics: Bulk Manufacturing of Off-Patent Active Pharmaceutical Ingredients, Generic Tablet Or Capsule Production, Parenteral Or Injectable Generic Manufacturing, Cost-Efficient Packaging for Unbranded Products, Licensing And Tech Transfer for Generic Products
Generic Pharmaceuticals Contract Manufacturing Market Trends: What’s Defining The Industry’s Next Phase?
Leading firms within the generic pharmaceutical contract manufacturing sector are broadening their range of services through the formation of specialized subsidiaries, addressing the increasing need for external development and manufacturing capabilities. The strategic establishment of these focused subsidiaries allows entities to optimize the manufacturing process for active pharmaceutical ingredients (APIs), guaranteeing adherence to regulations, capacity for growth, and streamlined operations throughout the entire drug development timeline. An example of this is seen in July 2025, when Lupin, an India-based generic pharmaceutical company, unveiled its new subsidiary, Lupin Manufacturing Solutions (LMS), to penetrate the contract development and manufacturing organization (CDMO) market. This specialized division is designed to facilitate the development, production, and distribution of APIs for its international pharmaceutical collaborators. Comprising a leadership team with extensive experience in the biotechnology and pharmaceutical sectors, the subsidiary is well-placed to provide premium contract services, assisting pharmaceutical enterprises in shortening their market entry timelines while upholding regulatory compliance and cost-effectiveness.
Generic Pharmaceuticals Contract Manufacturing Market Competitive Overview And Top Companies
Major companies operating in the generic pharmaceuticals contract manufacturing market are WuXi AppTec Co. Ltd., Recipharm AB, Siegfried Holding AG, Curia Global Inc., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Alcami Corp. Inc, Neuland Laboratories Limited.
View The Full Generic Pharmaceuticals Contract Manufacturing Market Report:
Generic Pharmaceuticals Contract Manufacturing Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model